Stoke therapeutics stock.

stok-10q_20220930.htm. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Stoke Therapeutics, Inc. and subsidiaries. Notes to condensed consolidated financial statements— (unaudited) of its common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement ...Jul. 25, 2023, 12:51 PM. Stoke Therapeutics Inc (NASDAQ:STOK) shares are trading lower after the company released new safety & efficacy data from STK-001 in the Phase 1/2a Studies (MONARCH ...Jul 24, 2023 · Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ... Company profile page for Stoke Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information

What is the target price for Stoke Therapeutics (STOK) stock? A. The latest price target for Stoke Therapeutics ( NASDAQ: STOK) was reported by Needham on Tuesday, November 7, 2023. The analyst ...

Nov 7, 2023 · Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Find the latest TScan Therapeutics, Inc. (TCRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently up 8.66% so far this month. During the month of June, Stoke Therapeutics Inc’s stock price has reached a high of $12.20 and a low of $10.69. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...Wedbush Lowers Stoke Therapeutics' Price Target to $13 From $18, Shifts STK-001 Launch Timing; Retains Outperform Rating. Aug. 08. MT. Stoke Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023.34.02%. Get the latest Stoke Therapeutics Inc (STOK) real-time quote, historical performance, charts, and other financial information to help you make more informed …Stoke Therapeutics Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for STOK stock stock is $21, which predicts an increase of 422.39%. The lowest target is $12 and the highest is $35. On average, analysts rate STOK stock stock as a strong buy.Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an ...

Complete Stoke Therapeutics Inc. stock information by Barron's. View real-time STOK stock price and news, along with industry-best analysis.

Form. Nov 28, 2023. 424B3. Nov 27, 2023. EFFECT. The Investor Relations website contains information about Aligos Therapeutics's business for stockholders, potential investors, and financial analysts.

stok-10q_20220930.htm. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Stoke Therapeutics, Inc. and subsidiaries. Notes to condensed consolidated financial statements— (unaudited) of its common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement ...For example, if you want to buy shares of Stoke Therapeutics, Inc., you could place a limit order to buy at $3.46 per share. If the price of Stoke Therapeutics, Inc. drops to $3.46 or less, your order will be executed. Your order will not be executed if the price never drops to $3.46. Limit orders can be helpful for investors who want to be ...Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...Stoke Therapeutics Inc’s ( STOK) price is currently down 10.24% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $7.22. Over the last year, Stoke Therapeutics Inc has hit prices as high as $24.97 and as low as $6.88. Year to date, Stoke Therapeutics Inc’s stock is ...Get the latest Stoke Therapeutics, Inc. (STOK) stock news and headlines to help you in your trading and investing decisions.Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics (STOK) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Stoke Therapeutics, with a price target of $25.00. The company’s shares closed last ...

Nov 8, 2023 · Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG remains neutral on the stock and ... Discover historical prices for STOK stock on Yahoo Finance. View daily, weekly or monthly format back to when Stoke Therapeutics, Inc. stock was issued.Stoke Therapeutics, Inc. (STOK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 3.7900 -0.0600 (-1.56%) At close: 04:00PM EST 3.8700 +0.08 (+2.11%) After hours: 07:28PM... Stoke Therapeutics Inc stock price live 3.88, this page displays NASDAQ STOK stock exchange data. View the STOK premarket stock price ahead of the market session or assess the after hours quote.12 hours ago · BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 - 5, in Orlando, Florida. Stoke Therapeutics ( NASDAQ: STOK) lost ~30% in value on Tuesday after the company announced new data from its Phase 1/2a Studies for the antisense oligonucleotide STK-001 targeted at patients ...

Nov 28, 2023 · Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The […] Stoke Therapeutics Inc’s ( STOK) price is currently down 10.24% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $7.22. Over the last year, Stoke Therapeutics Inc has hit prices as high as $24.97 and as low as $6.88. Year to date, Stoke Therapeutics Inc’s stock is ...

Find the latest TransCode Therapeutics, Inc. (RNAZ) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics Stock Price Chart Technical Analysis: Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and STOK is experiencing buying pressure, which is a positive indicator for future bullish movement.Stock analysis for Stoke Therapeutics Inc (STOK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 21, 2023 · BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 21, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at ... Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results. Find the latest Soleno Therapeutics, Inc. (SLNO) stock quote, history, news and other vital ...Nov 7, 2023 · Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program. ... Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and ...

What is the target price for Stoke Therapeutics (STOK) stock? A. The latest price target for Stoke Therapeutics ( NASDAQ: STOK) was reported by Needham on Tuesday, November 7, 2023. The analyst ...

Seth Harrison owns over 23,131 units of Stoke Therapeutics stock worth over $1,502,839 and over the last 4 years he sold STOK stock worth over $15,056,711. In addition, he makes $525,048 as Independent Chairman of the Board at Stoke Therapeutics. Wallmine is a radically better financial terminal.

Stoke Cares. Stoke employees care about building community both internally and externally. Company-sponsored activities include company gatherings and celebrations, efforts to give back to local communities, and opportunities to share interests and explore new pursuits — all within a respectful, friendly and diverse culture.The latest price target for . Stoke Therapeutics (NASDAQ: STOK) was reported by Needham on November 7, 2023.The analyst firm set a price target for $14.00 expecting STOK to rise to within 12 ...Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an ...Son STK-002 est un ASO en développement préclinique pour le traitement de l'atrophie optique autosomique dominante (ADOA). Le STK-002 est conçu pour augmenter l ...34.02%. Get the latest Stoke Therapeutics Inc (STOK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Find the latest Tenaya Therapeutics, Inc. (TNYA) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida.Nov 8, 2023 · Stoke Therapeutics Inc (STOK) has experienced a 27.30% rise in stock performance for the past week, with a 28.31% rise in the past month, and a -13.08% drop in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are at 6.66% for STOK. The simple moving average for the past 20 days is 25. ... Sep 14, 2023 · Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000.

Find the latest Atossa Therapeutics, Inc. (ATOS) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics, Inc. Common Stock (STOK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. rite aid bankruptcyinherited ira required minimum distributionrpiextriple a renters insurance Nov 21, 2023 · The Stoke Therapeutics, Inc. stock price fell by -6.47% on the last day (Tuesday, 21st Nov 2023) from $4.17 to $3.90. During the last trading day the stock fluctuated 5.91% from a day low at $3.89 to a day high of $4.12. The price has fallen in 7 of the last 10 days and is down by -19.59% for this period. Volume has increased on the last day by ... Dec 1, 2023 · Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Tuesday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.10. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.83 million. broker with the lowest spreadbest dental insurance in hawaii PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and ...Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s ... hyundai motor group stock Find the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics (NASDAQ:STOK), a leading biotechnology company, has experienced significant fluctuations in its stock price over the past year. As of July 28, 2023, shares of STOK stock opened at a modest $6.14 on Friday, far from its 12-month high of $22.87.Nov 17, 2023 · According to the issued ratings of 8 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $21.00 with a high price target of $35.00 and a low price target of $12.00.